Johnson & Johnson Q3 Results - Q3 Top Pharma Company Earnings Reports

View Johnson & Johnson's Q3 Earnings Report

FiercePharma says: Market reaction to Johnson & Johnson's earnings announcement reflects an overall worry about cost-cutting versus sales growth. Yes, J&J beat expectations, posting earnings of $1.20 per share, about 7 cents higher than analysts had estimated. But third-quarters sales came in at $15.1 billion, which fell short of those same estimates. At press time, the stock had fallen 2.62 percent, or $1.64, to $60.89. Read more of our coverage here...

Highlights:

  • Sales of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter
  • EPS of $1.20 increased 2.6% Versus 2008 Third Quarter

Check out J&J's current earnings estimates from CNN Money

J&J's Website: http://www.jnj.com/connect/

Johnson & Johnson Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

nyse
Pharma

Who were pharma's growth stars in Q4? Vertex, GSK, AZ and more

Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.

by Eric Sagonowsky
boardroom
Pharma

Pfizer, Mylan vets tapped for filled-out Viatris board, C-suite

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

by Kyle Blankenship
Eli Lilly
Pharma

Lilly's Cyramza narrowly wins lung cancer backing from FDA panel

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.

by Arlene Weintraub